These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17615369)

  • 1. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice.
    Parastatidis I; Thomson L; Fries DM; Moore RE; Tohyama J; Fu X; Hazen SL; Heijnen HF; Dennehy MK; Liebler DC; Rader DJ; Ischiropoulos H
    Circ Res; 2007 Aug; 101(4):368-76. PubMed ID: 17615369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor.
    Moore RE; Kawashiri MA; Kitajima K; Secreto A; Millar JS; Pratico D; Rader DJ
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1914-20. PubMed ID: 12933536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.
    Graversen JH; Laurberg JM; Andersen MH; Falk E; Nieland J; Christensen J; Etzerodt M; Thøgersen HC; Moestrup SK
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):170-7. PubMed ID: 18287885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice.
    Pastore L; Belalcazar LM; Oka K; Cela R; Lee B; Chan L; Beaudet AL
    Gene; 2004 Mar; 327(2):153-60. PubMed ID: 14980712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Hama S; Hough G; Fogelman AM
    Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
    Vaessen SF; Veldman RJ; Comijn EM; Snapper J; Sierts JA; van den Oever K; Beattie SG; Twisk J; Kuivenhoven JA
    J Gene Med; 2009 Aug; 11(8):697-707. PubMed ID: 19431216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.
    Hewing B; Parathath S; Barrett T; Chung WK; Astudillo YM; Hamada T; Ramkhelawon B; Tallant TC; Yusufishaq MS; Didonato JA; Huang Y; Buffa J; Berisha SZ; Smith JD; Hazen SL; Fisher EA
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):779-89. PubMed ID: 24407029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport.
    Shao B; Bergt C; Fu X; Green P; Voss JC; Oda MN; Oram JF; Heinecke JW
    J Biol Chem; 2005 Feb; 280(7):5983-93. PubMed ID: 15574409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.
    DiDonato JA; Aulak K; Huang Y; Wagner M; Gerstenecker G; Topbas C; Gogonea V; DiDonato AJ; Tang WHW; Mehl RA; Fox PL; Plow EF; Smith JD; Fisher EA; Hazen SL
    J Biol Chem; 2014 Apr; 289(15):10276-10292. PubMed ID: 24558038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis.
    Park SH; Kim JR; Park JE; Cho KH
    Eur J Clin Invest; 2007 Apr; 37(4):249-56. PubMed ID: 17373959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haptoglobin binding to apolipoprotein A-I prevents damage from hydroxyl radicals on its stimulatory activity of the enzyme lecithin-cholesterol acyl-transferase.
    Salvatore A; Cigliano L; Bucci EM; Corpillo D; Velasco S; Carlucci A; Pedone C; Abrescia P
    Biochemistry; 2007 Oct; 46(39):11158-68. PubMed ID: 17824618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
    Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
    Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model.
    Parolini C; Chiesa G; Gong E; Caligari S; Cortese MM; Koga T; Forte TM; Rubin EM
    Atherosclerosis; 2005 Dec; 183(2):222-9. PubMed ID: 16285990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase-mediated oxidation targets serum apolipoprotein A-I in diabetic patients and represents a potential mechanism leading to impaired anti-apoptotic activity of high density lipoprotein.
    Lu N; Xie S; Li J; Tian R; Peng YY
    Clin Chim Acta; 2015 Feb; 441():163-70. PubMed ID: 25528002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease.
    Sacksteder CA; Qian WJ; Knyushko TV; Wang H; Chin MH; Lacan G; Melega WP; Camp DG; Smith RD; Smith DJ; Squier TC; Bigelow DJ
    Biochemistry; 2006 Jul; 45(26):8009-22. PubMed ID: 16800626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression.
    Burillo E; Lindholt JS; Molina-Sánchez P; Jorge I; Martinez-Pinna R; Blanco-Colio LM; Tarin C; Torres-Fonseca MM; Esteban M; Laustsen J; Ramos-Mozo P; Calvo E; Lopez JA; Vega de Ceniga M; Michel JB; Egido J; Andrés V; Vazquéz J; Meilhac O; Martin-Ventura JL
    Thromb Haemost; 2015 Jun; 113(6):1335-46. PubMed ID: 25789510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant.
    Gomaraschi M; Baldassarre D; Amato M; Eligini S; Conca P; Sirtori CR; Franceschini G; Calabresi L
    Circulation; 2007 Nov; 116(19):2165-72. PubMed ID: 17967773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
    Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice.
    Wang Y; Zhao X; Jin H; Wei H; Li W; Bu D; Tang X; Ren Y; Tang C; Du J
    Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):173-9. PubMed ID: 18988885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions.
    Shao B; Pennathur S; Heinecke JW
    J Biol Chem; 2012 Feb; 287(9):6375-86. PubMed ID: 22219194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.